BURLINGAME, Calif.today announced that - Apexigen, Inc., an emerging biopharmaceutical company focused on the discovery and development of monoclonal antibody therapeutics, announced today that its partner, 3SBio [SSRX] of Shenyang, China, filed an Investigational New Drug (IND) application for APX001, also known as SSS07, with the State Food and Drug Administration (SFDA) in China.
Upon approval of the IND, APX001/SSS07 will be studied in clinical trials for the treatment of autoimmune and inflammatory diseases. APX001/SSS07 was discovered through the use of Apexigen's proprietary monoclonal antibody technologies and has been developed by 3SBio in China under a license from Apexigen. APX001/SSS07 is the second antibody discovered through the use of Apexigen's technologies for which an IND has been filed with the SFDA.
"We congratulate our colleagues at 3SBio on this IND filing," said Dr. Xiaodong Yang, President and CEO of Apexigen. "It represents the hard work of many individuals working collaboratively as a team to achieve the common goal. We look forward to continuing success in our collaboration."